| 摘要: |
| ［摘要］ 随着靶向治疗被广泛用于人类表皮生长因子受体-2（human epidermal growth factor receptor-2，HER-2）+乳腺癌患者，其所带来的心脏毒性，如左室射血分数下降、充血性心力衰竭等，已成为限制其使用的主要原因。该文主要就抗HER-2治疗相关心脏毒性的发生现状、防治进展进行综述。 |
| 关键词: 乳腺癌 人类表皮生长因子受体-2 靶向治疗 心脏毒性 |
| DOI：10.3969/j.issn.1674-3806.2019.04.03 |
| 分类号:R 737.9 |
| 基金项目:国家自然科学基金项目（编号：81372851） |
|
| Advances in the prophylaxis and treatment of cardiotoxicity associated with targeted therapy of breast cancer |
|
CHEN Hao-ran, KONG Ling-quan, WU Kai-nan
|
|
Department of Endocrine and Breast Surgery, the First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, China
|
| Abstract: |
| ［Abstract］ With the prevalence of targeted therapy in human epidermal growth factor receptor-2 (HER-2)+ breast cancer, its associated cardiotoxicity manifested as decline in left ventricular ejection fraction and congestive heart failure ect, has been the main reason for restricting its application. The current situation of occurrence of cardiotoxicity induced by anti-HER-2 therapy and its prophylactic & therapeutic advances are reviewed in this paper. |
| Key words: Braest cancer Human epidermal growth factor receptor-2 Targeted therapy Cardiotoxicity |
